Innovative and conventional “conservative” technologies for the treatment of uterine fibroids in Italy: a multidimensional assessment

Table 1 Results from the budget impact analysis assuming the NHS point of view

	Baseline scenario¹	Real-life scenario²	Difference €	Difference %
12-month clinical pathway, considering surgical procedure and follow-up	€ 5,981,802,665.58	€ 5,601,246,799.34	-€ 380,555,866.23	−6.36%
Re-intervention rate	€ 585,020,300.69	€ 544,232,524.43	-€ 40,787,776.27	−6.97%
Total	€ 6,566,822,966.27	€ 6,145,479,323.77	-€ 421,343,642.50	−6.42%
	Baseline scenario¹	Innovative scenario DH³	Difference €	Difference %
12-month clinical pathway, considering surgical procedure and follow-up	€ 5,981,802,665.58	€ 5,563,238,083.08	-€ 418,564,582.50	−7.00%
Re-intervention rate	€ 585,020,300.69	€ 541,165,322.12	-€ 43,854,978.58	−7.50%
Total	€ 6,566,822,966.27	€ 6,104,403,405.19	-€ 462,419,561.08	−7.04%

¹ The baseline scenario assumed that all the patients were treated with the surgical approach
² The real-life scenario assumed the implementation of all the technologies under assessment according to real-life practice case-mix (MRgFUS: 15.12%; UAE: 9.88%; Surgical setting: 75.00%)
³ The real-life scenario assumed the implementation of all the technologies under assessment according to real-life practice case-mix (MRgFUS: 15.12%; UAE: 9.88%; Surgical setting: 75.00%), considering all the MRgFUS to be conducted using a day-hospital approach

ISSN: 2191-1991